None

None

None

None

None

None

Study of Lademirsen (SAR339375) in Patients With Alport Syndrome

Primary Objectives: To assess the efficacy of lademirsen (SAR339375) in reducing the decline in renal function To assess the safety and tolerability of lademirsen (SAR339375) in subjects with Alport syndrome Secondary Objectives: To assess plasma pharmacokinetic (PK) parameters of the parent compound and its metabolites To assess the potential formation …

Study of SAR339375 in Patients With Alport Syndrome

Primary Objectives: To assess the efficacy of SAR339375 in reducing the decline in renal function To assess the safety and tolerability of SAR339375 Secondary Objectives: To assess plasma pharmacokinetic (PK) parameters of the parent compound and its metabolites To assess the immunogenicity of the SAR339375

Cohort of Patients With Systemic Sclerosis Within the Framework of the RESO Reference Centre

Systemic sclerosis (SSc) is a rare form of connective tissue disease characterized by vascular involvement and the intensity of fibrosis. The lack of available treatment is largely due to the very fragmented understanding of the pathophysiology of SSc.

Rheumatology Patient Registry and Biorepository

To facilitate clinical, basic science, and translational research projects involving the study of rheumatic diseases.